Background The Risk Evaluation and Mitigation Strategy (REMS) for retigabine/ezogabine (RTG/EZG) required an evaluation of the effectiveness of the communication plan to communicate about the risks with use of RTG/EZG. Objective GlaxoSmithKline conducted a survey to assess understanding of the risk of urinary retention (UR) with RTG/EZG and to evaluate the effectiveness of the communication plan. Methods This was a US-based, cross-sectional, non-interventional, observational survey, conducted from February to April 2013, of physicians who had prescribed RTG/ EZG in the past year, and pharmacists who had dispensed an antiepileptic drug within the past 3 months. Thirteen primary objective questions (five specific to UR risk) were included in the survey, which assessed healthcare professionals' (HCPs') understanding of UR risk and symptoms of acute UR associated with RTG/EZG. The primary outcome was the proportion of HCPs correctly answering each question. For each question, a proportion of correct responses C80 % was considered to represent sufficient understanding of associated risks. Results Of 1028 HCPs screened, 373 participated. Six of 13 questions (3/5 specific to UR risk) met the C80 %
threshold for correct responses in the physician cohort. No questions achieved this threshold in the total pharmacist group; however, four questions scored C80 % when stratified by pharmacists who had dispensed RTG/ EZG. Conclusions Results demonstrated a mixed level of understanding of aspects of UR risk associated with RTG/ EZG, although some risk questions did not meet the 80 % threshold, especially among pharmacists. This is likely to have been due to the short time that RTG/EZG has been available and its limited use. This study provides the first evaluation of the REMS communication plan on the risk of UR with RTG/EZG.
Introduction
Retigabine (RTG; international nonproprietary name)/ ezogabine (EZG; US adopted name) is an antiepileptic drug (AED) approved in the US (as POTIGA TM , GlaxoSmithKline [GSK] and Valeant) for the adjunctive treatment of partial-onset seizures in adults who have responded inadequately to several treatments and for whom the benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity [1] . In clinical studies investigating the efficacy and safety of RTG/EZG, an increased risk of urinary retention (UR) was reported in patients receiving RTG/EZG compared with placebo [2] [3] [4] [5] [6] .
RTG/EZG was approved in June 2011 with a US Food and Drug Administration (FDA) requirement for a Risk Evaluation and Mitigation Strategy (REMS) [7] . According to the FDA Amendments Act of 2007, the FDA may require a drug manufacturer to submit a REMS, which is intended to manage known or potential serious risks associated with a drug and to ensure that the benefits of the drug outweigh the risks [8, 9] . The REMS for RTG/EZG consisted of a communication plan for healthcare professionals (HCPs), including prescribing physicians and dispensing pharmacists, designed to disseminate information on the risk of UR with RTG/EZG and highlight the importance of advising patients to seek immediate attention for symptoms of UR, including inability to urinate and/or pain with urination. The communication plan had two elements: (i) a Dear Healthcare Professional (DHCP) letter, disseminated within 4 weeks of first retail availability (May 7, 2012) and annually for the following 2 years; and (ii) a REMS program website available at the time of launch (April 16, 2012; no longer active). The delay between the approval of the new drug application (NDA; June, 2011) and retail availability was caused by the requirement for RTG/EZG to be reviewed by the US Drug Enforcement Administration (DEA), in line with the Controlled Substances Act, in order to determine the scheduling status.
As a condition of approval, the FDA required that GSK assess this communication plan's effectiveness. Accordingly, a survey was conducted among a sample of HCPs to evaluate knowledge of UR risk with RTG/EZG [10] . The survey focused on the risks described in the DHCP letter for RTG/EZG, and assessed where HCPs prefer to seek information for RTG/EZG (e.g., DHCP letters, website, product labeling). Here we report the results of this survey.
Methods

Study Design
This was a cross-sectional, non-interventional, observational survey of HCPs who prescribe RTG/EZG or dispense AEDs. The study did not include intervention; therefore, institutional review board approval was not deemed necessary.
Sampling and Study Population
From a Concentrics Research market research partner's custom database of more than 668,000 geographically and therapeutically diverse US HCPs, approximately 14,000 eligible physicians and pharmacists were contacted from a demographically representative population who prescribe RTG/EZG (neurologists, neurosurgeons, epileptologists), or dispense AEDs (pharmacists). The original mailing list for the DHCP letter included prescribers, emergency room physicians and urologists, the HCPs most likely to come into contact with RTG/EZG-treated patients who may have UR symptoms. This survey focused only on recruiting potential prescribers and the overlap between the DHCP mailing list and the Concentrics database is not known.
Survey Inclusion, Exclusion, and Withdrawal Criteria
Inclusion criteria included practicing physicians who had prescribed RTG/EZG within the past year, and practicing pharmacists who had filled a prescription for at least one AED within the past 3 months. Physicians and pharmacists currently employed by, or who were representatives of, a pharmaceutical company or manufacturer of medicines or healthcare products, or who were contributors to, or editors of, published guideline committees for epilepsy or UR, were ineligible. Additionally, HCPs who previously participated in the pilot REMS study for RTG/EZG, or who were employees of GSK or Concentrics Research, were excluded. HCPs could withdraw from the study at any time. 
Screening and Baseline Assessments
Statistical Analysis
Baseline assessments were summarized by using proportions (%) for categorical data. The primary outcome was the proportion of HCPs correctly answering each question related to understanding of risks associated with RTG/ EZG. At least 80 % of correct responses for each question was considered to represent sufficient understanding of the risks associated with RTG/EZG. This threshold was determined on the basis of experience from similar studies previously planned by GSK and approved by the FDA [11] . In a REMS workshop in July 2012, the FDA cites the 80 % threshold as a level that is generally accepted for the survey responses [12] , though the discussion on setting standardized thresholds for REMS assessments is ongoing [13] . The proportion of correct answers to survey questions was summarized overall and by demographic subgroups. Data were grouped into subcategories to identify possible trends in understanding, including demographics, type of HCP, RTG/EZG prescribing/dispensing, and other practice/prescribing characteristics.
Results
Subject Disposition
Of 1028 HCPs who were recruited and screened, 373 physicians (n = 168) and pharmacists (n = 205) completed the survey (Fig. 1 ). All respondents completed the survey online, and none completed the survey by phone.
Demographics and Baseline Characteristics
Physicians reported that their primary specialty was neurology (64 %) or epileptology (36 %). Pharmacists reported community/retail (55 %) or hospital/clinic (45 %) as their primary specialty. Most HCPs had been practicing medicine/pharmacy and prescribing/dispensing AEDs for 5-35 years. Prescribing physicians treated patients across all ages, and most reported a total number of more than 1000 patients, more than 100 of whom had epilepsy. Sixty percent of physicians had prescribed, and 41 % of pharmacists had filled prescriptions for AEDs to more than 50 patients monthly during the past year. Most pharmacists had not dispensed (77 %) RTG/EZG or answered (83 %) patients' questions about RTG/EZG in the past year. Of those who had done so, 44 % reported having dispensed RTG/EZG for only 1-3 months and most reported prescribing (physicians, 52 %) or dispensing (pharmacists, 66 %) RTG/EZG to only 1-2 patients within the past year.
Survey Results
The distribution of responses to questions assessing HCPs' understanding of the risks associated with RTG/EZG is shown in Table 1 . Of the five questions related specifically to the risk of UR associated with RTG/EZG, three (Q3, Q8, Q13) were correctly answered by more than 80 % of physicians and met the pre-defined threshold, whereas two (Q7 and Q12) fell below the target threshold. Of the questions not specifically related to UR risk, Q1, Q2, and Q11.1 were answered correctly by more than 80 % of physicians (Q11 was a single question with five parts that are shown separately); the remaining questions (Q4, Q5, Q6, Q9, Q10, Q11.2, Q11.3, Q11.4, Q11.5) had an average percent correct response of 59 %.
None of the questions for the pharmacist cohort achieved the 80 % threshold. However, when stratified by pharmacists who had dispensed RTG/EZG (n = 32), the established threshold was met by four questions (Q1, Q3, Q8, Q11.1), two of which (Q3, Q8) were specifically related to UR risk (Table 1) .
A series of profiling questions asked HCPs how they learned about the risks associated with RTG/EZG and invited them to select up to three options for how they would prefer to learn about such risks in the future. Responses to these questions are presented in Table 2 . The majority of HCPs did not learn about the risks associated with RTG/EZG from a DHCP letter. Notably, 82 % of physicians and 91 % of pharmacists gave a negative response when asked if the DHCP letter was their source of information about RTG/EZG-associated risks. Most physicians reported learning about these risks from the RTG/EZG product label (78 %) or from a GSK sales representative (60 %), whereas pharmacists reported learning from the RTG/EZG product label (46 %), other HCPs (22 %), or the GSK product website (20 %). Physicians reported interest in learning about the risks associated with RTG/EZG in the future through GSKsponsored educational meetings (55 %), sales representatives (46 %), or product labeling (36 %). Pharmacists preferred to receive information from product labeling (49 %), GSK-sponsored educational meetings (36 %), sales representatives (35 %), or a DHCP letter (31 %).
Discussion
This study provides an indication of the effectiveness of the RTG/EZG REMS communication plan, as evaluated by a survey of prescribing physicians and dispensing pharmacists, to assess HCPs' recall of the risks and symptoms of UR associated with RTG/EZG. Overall, the surveyed population encompassed HCPs with 5-35 years of experience in practice; most had considerable experience in prescribing or dispensing AEDs. RTG/EZG has been available only since May 2012, and prescribing of the drug has been modest. Both of these factors explain the relatively low level of experience in prescribing and dispensing RTG/EZG among the HCPs surveyed.
The original proposal had been to survey all potential AED prescribers, but the RTG/EZG launch was delayed due to the DEA assessment of the scheduling status and sales showed that RTG/EZG uptake was low, so the sample of HCPs was enriched for those who had some experience with RTG/EZG. The selection criteria differed between prescribers and pharmacists. Prescribers were mainly specialists likely to see epilepsy patients, but pharmacists were generalists and could not be assumed to have any experience with dispensing RTG/EZG. The shorter time period for requiring dispensing of AEDs by pharmacists was selected to enrich the possibility of pharmacist experience with RTG/EZG. One physician was removed from the study due to inconsistencies between indicated primary specialty during screening and on questionnaire. RTG/EZG retigabine/ezogabine Generally, among physicians, the survey results revealed a mixed level of understanding of several aspects of the UR risk associated with RTG/EZG, although a number of risk questions did not meet the pre-defined 80 % correct response threshold. The lower understanding of RTG/EZG-associated UR risk within the pharmacist group can be explained by a lack of familiarity and experience with dispensing RTG/EZG among retail and hospital pharmacists due to the short time that RTG/EZG has been available and its low rate of prescribing.
Although the survey included a considerable number of physicians and pharmacists, the sample may not be fully representative of HCPs who prescribe or dispense RTG/ The US branded name for RTG/EZG (POTIGA TM ) was used throughout the survey. Among the 30 survey questions, questions Q29.1 through Q30 pertained to HCP profiling HCP healthcare provider, RTG/EZG retigabine/ezogabine EZG. To limit this potential bias, HCPs were recruited from a large online database of geographically and demographically diverse US HCPs, rather than by targeting only high prescribers of RTG/EZG. Because the small sample size in certain subgroups may have resulted in low precision, data were grouped into appropriate subcategories to identify possible trends in understanding. As this was an online survey, it was not possible to detect whether or not HCPs used any reference materials while taking the survey.
Overall, in this first evaluation of the REMS communication plan to disseminate information on the risks of UR associated with RTG/EZG treatment, physicians demonstrated a mixed level of understanding of the symptoms and of risks associated with RTG/EZG use. Pharmacists displayed a lower level of understanding, probably due to the short time that RTG/EZG has been available for prescription. One key insight gained from the survey was that the questions should be focused on the specific risks, and the addition of extra questions to mask the intent of the survey from respondents may have added complexity and confusion. The EU survey was modified accordingly following the REMS survey experience [14] . The results of the survey did not indicate a need for alternative or additional measures, beyond the originally proposed REMS measures, to enhance the understanding of the risk of UR with POTIGA TM . The FDA announcement on pigmentation in retigabine patients was released on 26 April 2013 [15] . At the start the survey, these risks
were not yet known. After the safety issues emerged, the planned distribution of annual DHCP letters as part of the original REMS was delayed in agreement with the FDA and ongoing discussions took place with the FDA on the next steps.
